Italian biotech Cassiopea has won US approval for Winlevi, a topical therapy it says is the first new approach to treating acne in nearly 40 years. An androgen receptor inhibitor, Winlevi ...
Cassiopea has filled that gap with a first-in-class acne treatment, Winlevi, a topical androgen receptor (AR) inhibitor. Although the exact mechanism of action is unknown, in vitro studies show ...
Cosmo Pharmaceuticals N.V. (OTCPK:CMOPF) Monday said that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi in the United Kingdom.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback